1. Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer 
David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono 
European Urology Focus 
Volume 2, Issue 5, Pages (December 2016)
DOI: /j.euf
Copyright © 2016 European Association of Urology Terms and Conditions

2. Fig. 1
Natural history of the prostate cancer. Disease states as defined by the Prostate Cancer Clinical Trials Working Group 3 criteria. PSA = prostate-specific antigen; nmCRPC = nonmetastatic castration-resitant prostate cancer; mCRPC = metastatic CRPC. Taken from: Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34:1402–18 [9]. Permission requested from the Journal of Clinical Oncology.
European Urology Focus 2016 2, DOI: ( /j.euf )
Copyright © 2016 European Association of Urology Terms and Conditions